Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486174 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL1337447 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL1486172 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL28520254 | 1.00 | AAK1 (0.32) | AAK1MMP13TP53MEN1GAA | |
| SCHEMBL67120 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL59435 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL2160514 | 0.87 | CA1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL23749797 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL26449279 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL26449223 | 0.86 | HDAC6 (0.32) | AAK1MMP13HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813659-A | Chiral aryl iodine catalyst with threonine as chiral source, and synthetic method and application thereof | 浙江工业大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-2782567-B1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | UNIV CALIFORNIA (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | FOND ST ITALIANO TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-9353075-B2 | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | disclosed |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | NAAA, FAAH, FAAH2 | AAK1 1020/4885MMP13 1645/4885TP53 4264/4885 |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | F2, F11, SERPINC1 | AAK1 2578/4885MMP13 3580/4885TP53 4845/4885 |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | NAAA, FAAH, FAAH2 | AAK1 1020/4885MMP13 1645/4885TP53 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.